Personalized Medicine Approach Provides More Benefit for Patients with High Cholesterol than Current Guidelines

February 24, 2010 | by
ResearchBlogging.org

Statins are a class of drugs that lower cholesterol and thereby reduce the risk of heart disease and stroke. They work by preventing the synthesis of low-density lipoprotein (LDL or “bad cholesterol”) in the liver and promoting its clearance from the blood. They are the most effective cholesterol-lowering drugs currently available and are the cornerstone of the National Heart, Lung, and Blood Institute’s National Cholesterol Education Program (NCEP) treatment guidelines.

The NCEP recommends a “treat-to-target” strategy, in which patients are given specific statin doses to achieve a desired level of LDL cholesterol in the blood. In this case, low LDL cholesterol is the “target.” Yet some physicians are questioning whether treating to any target is the best approach to fighting disease. A recent study in the Annals of Internal Medicine suggests that “tailored treatment”, an approach attempts to practice personalized medicine by estimating three factors, is more effective than a treat-to-target strategy [1].

Scientists Map Genetic Regulatory Elements for the Heart

February 17, 2010 | by

Scientists have devised a new computational model that can be used to reveal genetic regulatory elements responsible for development of the human heart and maintenance of its function.

Although the teams focused on the heart, the computational method they developed is broadly applicable to other tissues, and was successfully used to identify regulatory elements for cells of the limbs and brain. Cataloging these regulatory sequences may improve understanding of diseases and lays the groundwork for improved medical treatments.

The research, conducted by scientists at the National Institutes of Health’s National Center for Biotechnology Information (NCBI) and the University of Chicago, is published in the March 2010 issue of Genome Research and is available online.

Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection

February 2, 2010 | by

Scientists have found that cancer patients produce antibodies that target abnormal glycoproteins (proteins with sugar molecules attached) made by their tumors. The result of this work suggests that antitumor antibodies in the blood may provide a fruitful source of sensitive biomarkers for cancer detection. The study, supported in part by the National Cancer Institute (NCI), part of the National Institutes of Health, appears in the Feb. 15, 2010 issue of the journal Cancer Research.

Cancer cells secrete mucins into the bloodstream

Gene Mutations Reveal Potential New Targets for Treating a Type of Non-Hodgkin’s Lymphoma

January 11, 2010 | by

Researchers have discovered genetic mutations that may contribute to the development of an aggressive form of non-Hodgkin’s lymphoma. These findings provide insight into a mechanism that cancer cells may use to survive, thus identifying potential new targets for treatment of the disease. The study conducted by researchers at the National Cancer Institute (NCI), the National Institute for Allergy and Infectious Diseases, and the National Human Genome Research Institute, components of the National Institutes of Health, and colleagues appeared Jan. 7, 2010, in Nature.

Chromosome Telomeres and the Nobel Prize for Medicine

October 9, 2009 | by

nobel medal in medicineThe 2009 Nobel Prize in Physiology or Medicine was announced earlier this week. The prize was awarded to three U.S. scientists for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.

Two women, Elizabeth H. Blackburn, age 61, at the University of California in San Francisco, and Carol W. Greider, age 48, at Johns Hopkins University School of Medicine in Baltimore along with one man, Jack W. Szostak, age 57, at Harvard Medical School, will share the $1.4 million prize.